Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)

NCT06463184 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped funding issues

Conditions

Recurrent High-grade Glioma

Interventions

DRUG: Xevinapant

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]